Healthcare Expenditure Trajectories in the Last 5 Years of Life: A Retrospective Cohort Study of Decedents with Advanced Cancer and End-Stage Organ Diseases [0.03%]
生命最后五年医疗费用趋势分析：晚期癌症与终末期器官疾病逝者群体的回溯性研究
Sheryl Hui-Xian Ng,Palvinder Kaur,Laurence Lean Chin Tan et al.
Sheryl Hui-Xian Ng et al.
Background: Patients with nonmalignant end-stage organ diseases often incur healthcare costs in the last year of life that are disproportionately higher than in the period prior. Studies on healthcare expenditure (HCE) tr...
Effects of Generic Entry on Market Shares and Prices of Originator Drugs: Evidence from Chinese Pharmaceutical Market [0.03%]
专利药品市场中的市场份额和价格对通用药物进入的反应——来自中国医药市场的证据
Weimiao Li,Xiaoyu Li,Yaoguang He et al.
Weimiao Li et al.
Objectives: This article analyzes how market shares and prices for brand-name drugs are affected by generic competition in China. Methods: ...
Predicting Danish EQ-5D-5L Utilities Based on United Kingdom EQ-5D-3L Utilities for Use in Health Economic Models [0.03%]
基于英国EQ-5D-3L效用值预测丹麦EQ-5D-5L效用值用于卫生经济学模型中的应用
Einar B Torkilseng,Nathan Clarke,Liza Sopina et al.
Einar B Torkilseng et al.
Objectives: Since 2021, the Danish Medicines Council recommends the use of the Danish EQ-5D-5L value set when estimating utilities. The aim of this research was to develop and validate an algorithm that can accurately pre...
Cost Effectiveness of Left Ventricular Assist Devices (LVADs) as Destination Therapy: A Systematic Review [0.03%]
左心室辅助装置（LVAD）作为终点治疗的成本效益：系统性评价
Tuba Saygın Avşar,Louise Jackson,Pelham Barton et al.
Tuba Saygın Avşar et al.
Objectives: Left ventricular assist devices (LVADs) can extend life and improve quality of life among advanced heart failure patients ineligible for transplantation (destination therapy). High-quality evidence on the cost...
Do We Understand Unmet Need? A Proposal to Use Length-Of-Life Equivalent (LOLE) as a Patient-Centric Measure of Unmet Need [0.03%]
我们理解未满足的需求吗？提出使用寿命当量（LOLE）作为以患者为中心的未满足需求测量方法
Kevin Marsh,Robert F Reynolds,Linda Nelsen et al.
Kevin Marsh et al.
Many decision-makers have emphasized the importance of leveraging patient experience data to measure unmet need. However, there is no standardized, patient-centric unmet need measure that formalizes how the value judgements inherent in such...
Publisher Correction: Pricing for Multi-Indication Drugs in the Italian Regulatory Context [0.03%]
出版更正：意大利监管环境中的多适应症药物定价问题
Maria Grazia Ursino,Annalisa Milano,Filippo Viti De Angelis et al.
Maria Grazia Ursino et al.
Published Erratum
PharmacoEconomics - open. 2025 Feb 14. DOI:10.1007/s41669-025-00566-2 2025
So Many Choices, So Little Value: Potential Savings from Selecting Cost-Effective Proton Pump Inhibitors [0.03%]
如此多的选择，如此微薄的价值：通过选择具有成本效益的质子泵抑制剂来节约潜在费用
Hye-Young Kwon
Hye-Young Kwon
Background: Given that Korea lacks measures to promote cost-effective prescribing, this study investigated the efficiency of prescribers' decision-making when faced with the choice of 398 products containing 15 proton pum...
Burden of Disease and Cost of Illness of Triple-Negative Breast Cancer in Portugal [0.03%]
葡萄牙三阴性乳腺癌的疾病负担和疾病成本
Joana Silva,Gabriela Sousa,Luís Costa et al.
Joana Silva et al.
Background: Triple-negative breast cancer accounts for 15% of all breast cancer cases, and it has a lower survival rate and higher incidence of early recurrence, particularly during the first 10 years after diagnosis. ...
COVID-19 Vaccine Preferences in China: A Comparison of Discrete Choice Experiment and Profile Case Best-Worst Scaling [0.03%]
中国新冠疫苗偏好：分组选择实验和配置案例最佳-最差量表的对比研究
Enxue Chang,Yanni Jia,Xiaoying Zhu et al.
Enxue Chang et al.
Objectives: Little is known about the diversity of residents' preferences for COVID-19 vaccines during the time when COVID-19 management was downgraded in China. This study aims to investigate these preferences using disc...
Very Early Health Technology Assessment for Potential Predictive Biomarkers in the Treatment of Advanced Non-Small Cell Lung Cancer [0.03%]
用于治疗晚期非小细胞肺癌的潜在预测生物标志物的非常早期的卫生技术评估
Leila-Sophie Otten,Alessandra I G Buma,Berber Piet et al.
Leila-Sophie Otten et al.
Objectives: Immune checkpoint inhibitor (ICI)-containing treatment is currently prescribed as first-line treatment for all patients with advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. How...